News
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024
Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Transcenta
By: prnewswire_apac
- Sep 19 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS